



Attorney Docket No. VPI/02-116 US

*ITW*

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/700,333  
Confirmation No.: 5159  
Filing Date: November 3, 2003  
Examiner: Venkataraman Balasubramanian  
Group Art Unit: 1624  
Applicants: Mark Ledebøer et al.  
For: COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER  
PROTEIN KINASES

June 28, 2006  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copies of references Citation Nos. **A1; B6-B7** are attached.
- ☐ Copy(ies) of references Citation No(s). \_\_\_\_\_ was/were filed in application U.S. Application No(s). \_\_\_\_\_ filed \_\_\_\_\_, from which this application claims priority under 35 U.S.C. § 120.
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. \_\_\_\_\_ is attached herewith.

- (b) ☐ No fee is believed due because:

- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

07/06/2006 EFLORES 00000017 500725 10700333

01 FC:1806 180.00 DA

(c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or

☒ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

(d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and

☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or


☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and

☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.


Applicants: Mark Ledebøer et al.  
Application No.: 10/700,333

Respectfully submitted,



Karen E. Brown, Reg. No. 43,866  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483  
Customer No.: 27916

I hereby certify that this correspondence and any documents referred to as attached hereto are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:  
Mail Stop Amendment, Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450 on June 28, 2006.

  
\_\_\_\_\_  
Lisa M. Romano

Signature



<b>Modified Form 149/PTO</b> <b>TRADEMARK OFFICE</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/700,333
	<b>Filing Date</b>	November 3, 2003
	<b>First Named Inventor</b>	Mark Ledebocr
	<b>Group Art Unit</b>	1624
	<b>Examiner Name</b>	Venkataraman Balasubramanian
	<b>Attorney Docket Number</b>	VPI/02-116 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date/ Publication date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	US2004/0176271 A1	September 9, 2004	Vertex Pharmaceuticals Incorporated	514	2	11/5/2003

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B6	WO	03/030909 A1	Bayer Corporation	17 April 2003		
	B7	WO	02/079193 A1	Cyclacel Limited	10 October 2002		

OTHER NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.